| Monday 5 March
|
|
From 08:30
|
|
Registration and coffee
Hall 3 foyer
|
| |
|
|
|
10:00 10:45
|
|
Basic Review Lecture
Applications of proteomics in translational research
Hall 1
Chair: J Davis (Manchester)
|
|
S74
|
Applications of proteomics in translational research
W Kolch ( (Glasgow))
|
| |
|
|
|
10:45 12:45
|
|
Molecular Endocrinology Workshop: Nuclear hormone receptor-chromatin interactions: new approaches and insight into dynamics
Hall 9
Chairs: J Gustafsson (Novum, Sweden) & C McCabe (Birmingham)
|
| 10:45 |
S72
|
Chip-chip approaches to understanding ER function
J Carroll ( (Boston, USA))
|
| 11:45 |
S73
|
Dynamics of nuclear receptor interactions on chromatin
G Hager ( (Bethesda, USA))
|
| |
|
|
|
10:45 12:45
|
|
Symposium 1: Transdifferntiation in the endocrine system
The ability of specific endocrine organs to differentiate their cellular population in order to meet altered physiological requirements is important in the development of endocrine pathologies
Hall 11
Chairs: D Tosh (Bath) & S Ball (Newcastle upon Tyne)
|
| 10:45 |
S9
|
Fibroblasts and tissue remodelling: defining a role for fibroblasts in the persistence of chronic inflammation
C Buckley ( (Birmingham))
|
| 11:15 |
S10
|
Transdifferentiation in the osteoblast
M Nuttall ( (Malvern, USA))
|
| 11:45 |
S11
|
Plasticity of the adipose organ
S Cinti ( (Ancona, Italy))
|
| 12:15 |
S12
|
Pancreatic transdifferentiation and the treatment of liver damage
M Wright ( (Aberdeen))
|
| |
|
|
|
10:45 12:45
|
|
Clinical Management Workshop 1: Management of endocrine disorders in pregnancy: the mother and the child
Supported by Clinical Endocrinology
Hall 1
Chairs: C Nelson-Piercy (London) & M Blot (Newcastle upon Tyne)
|
| 10:45 |
S45
|
Hyperglycaemia in pregnancy
D McCance ( (Belfast))
|
| 11:15 |
S46
|
CAH - pregnancy and antenatal glucocorticoid treatment
S Lajic ( (Stockholm, Sweden))
|
| 11:45 |
S47
|
Thyroid disease in pregnancy
S Mandel ( (Pennsylvania, USA))
|
| 12:15 |
S48
|
Maternal vitamin D status in pregnancy and risk to the child
Z Mughal ( (Manchester))
|
| |
|
|
|
12:45 14:15
|
|
Lunch and posters
Hall 3
|
| |
|
|
|
12:50 14:05
|
|
Open access and your research
Opening up the litrature or closing down journals?
Hall 9
Chair: S Thorn (Society for Endocrinology)
|
| 12:55 |
|
Open Access: what is it, and how might it affect your Society?
S Byford (Society for Endocrinology)
|
| 13:14 |
|
Do researchers think a move to Open Access would serve their interest better or worse?
I Rowlands (CIBER, University College London)
|
| 13:40 |
|
Is the 'author pays' model financially viable and does it achieve wider dissemination?
M Richardson (Managing Director, Oxford University Press)
|
| 14:05 |
|
Discussion
|
| |
|
|
|
14.15 16.15
|
|
Symposium 2: Thyroid and autoimmunity
An update on thyroid autoimmunity: T cells, animal models, TSH receptor and clinical aspects of TSH receptor antibodies
Hall 1
Chairs: S Pearce (Newcastle upon Tyne) & R Aijan (Leeds)
|
| 14:15 |
S13
|
Pathogenic and regulatory T cells in a humanised model of hypothyroidism
S Quaratino (Southampton)
|
| 14:45 |
S14
|
Novel animal models of Grave's hyperthyroidism
S McLachlan (Los Angeles, USA)
|
| 15:15 |
S15
|
The TSH receptor: from natural variants to structure and function
G Vassart (Brussels, Belgium)
|
| 15:45 |
S16
|
TSH receptor antibodies - should we measure them and if so how?
A Weetman (Sheffield)
|
| |
|
|
|
14.15 16.15
|
|
Oral Communications 1: Steroid synthesis and action
Supported by the Clinical Endocrinology Trust
Hall 11
Chairs: J Connell (Glasgow) & K Forbes (Manchester)
|
| 14:15 |
OC1
|
Monogenic Polycystic ovary syndrome (PCOS) due to novel mutations in the H6PD gene - Apparent Cortisone Reductase Deficiency (ACRD).
A Slabbert;
G Lavery;
J Connell;
E Walker;
P Stewart;
|
| 14:30 |
OC2
|
Mouse Melanocortin-2 receptor accessory protein: expression pattern and protein characterisation
I Almiro do Vale;
M Egertová;
L Guasti;
M Elphick;
A Clark;
|
| 14:45 |
OC3
|
Transcriptional regulation of 11beta-hydroxysteroid dehydrogenase type 1 under the synergistic control of glucocorticoids and cytokines
K Kaur;
G Lavery;
E Walker;
P Stewart;
M Hewison;
M Cooper;
E Rabbitt;
|
| 15:00 |
OC4
|
Modulation of membrane initiated glucocorticoid signalling by caveolin-1
L Matthews;
A Berry;
J Ohanian;
V Ohanian;
D Ray;
|
| 15:15 |
OC5
|
Hexose-6-phosphate dehydrogenase: a novel regulator of glucocorticoid hormone action
Society for Endocrinology/Clinical Endocrinology Trust Young Endocrinologist Basic Science Prize Lecture
G Lavery;
|
| 15:45 |
OC6
|
A novel tethering mechanism explains cell type specific glucocorticoid repression of macrophage migration inhibitory factor (MIF)
L Elsby;
Z Alourfi;
R Donn;
D Ray;
|
| 16:00 |
OC7
|
Differential effects of P450 oxidoreductase mutants on CYP17 activity provides evidence for an alternative pathway in human androgen biosynthesis
V Dhir;
H Ivison;
N Krone;
P Stewart;
C Shackleton;
W Arlt;
|
| |
|
|
|
14.15 16.15
|
|
Oral communications 2: Clinical and translational endocrinology
Hall 9
Chairs: S Gough (Birmingham) & A Munir (Sheffield)
|
| 14:15 |
OC8
|
Effect of once-yearly infusion of zoledronic acid 5mg in postmenopausal women with osteoporosis
R Eastell;
D Black;
J Cauley;
F Cosman;
S Cummings;
P Delmas;
E Eriksen;
W Fraser;
T Hue;
P Lakatos;
P Leung;
Z Man;
A McLellan;
P Mesenbrink;
D Reid;
I Reid;
S Boonen;
|
| 14:30 |
OC9
|
A novel homozygous inactivating mutation, Pro339Thr, of the calcium-sensing receptor is associated with isolated primary hyperparathyroidism
F Hannan;
M Nesbit;
P Christie;
W Lissens;
M Bex;
R Bouillon;
R Thakker;
|
| 14:45 |
OC10
|
Expression of the orphan nuclear receptors oestrogen receptor related (ERR) alpha and beta in the human endometrium: implications for oestrogen receptor signalling.
V Bombail;
S MacPherson;
K Kerr;
F McGarry;
H Critchley;
P Saunders;
|
| 15:00 |
OC11
|
Reduced 5α-reductase activity in peripheral blood mononuclear cells in polycystic ovarian syndrome - a compensatory mechanism for androgen excess ?
F Hammer;
N Bozhinova;
B Hughes;
M Fassnacht;
P Stewart;
B Allolio;
W Arlt;
|
| 15:15 |
OC12
|
Local and systemic consequences of glucocorticoid metabolism in synovium
R Hardy;
M Cooper;
P Stewart;
C Buckley;
K Raza;
E Rabbitt;
M Cooper;
|
| 15:30 |
OC13
|
Relative protection of cortical bone in women with complete androgen insensitivity syndrome compared to women with gonadal dysgensis
T Han;
D Goswami;
S Trikudanathan;
S Creighton;
G Conway;
|
| 15:45 |
OC14
|
A two-centre experience of long-term pegvisomant therapy in 58 patients
C Higham;
T Chung;
W Drake;
P Trainer;
|
| 16:00 |
OC15
|
Biological variability of Insulin resistance in polycystic ovarian syndrome after treatment with metformin, orlistat and pioglitazone
L Cho;
S Gonzalez;
S Holding;
E Kilpatrick;
S Atkin;
|
| |
|
|
|
16.15 16.35
|
|
Tea
Hall 3
|
| |
|
|
|
16.35 17.05
|
|
Society for Endocrinology Annual General Meeting
Hall 1
|
| |
|
|
|
17.10 18.00
|
|
Society for Endocrinology Dale Medal Lecture
Dale Medallist Professor Steven Lamberts will discuss the pathophysiology of somatostatin receptors in man, demonstrating how every part of the course of events from ligand-receptor binding and internalisation to the activation of intracellular pathways has been translated in clinically meaningful applications
Hall 3
Chair: J Wass (Oxford)
|
|
S1
|
The ever-expanding role of somatostatin receptors in endocrine disease
S Lamberts (Rotterdam, The Netherlands)
|
| |
|
|
|
18.00 19.30
|
|
Welcome Reception
Hall 3
|
| |
|
|
| Tuesday 6 March
|
|
07.15 08.00
|
|
Clinical Expert 1: Management of non-functioning pituitary tumour
Hall 9
Chair: T Kearney (Salford)
J Bevan (Aberdeen)
|
| |
|
|
|
07.15 08.00
|
|
Clinical Expert 2: Management of delayed puberty
Hall 11
Chair: F Ahmed (Glasgow)
C Kelnar (Edinburgh)
|
| |
|
|
|
08.15 10.15
|
|
Symposium 3: Endocrinology of senescence
Endocrine function is altered in the ageing organism. New roles for traditional hormones have recently been discribed which may elucidate novel endocrine therapies
Genourously supported by Ipsen Ltd
Hall 11
Chairs: J Seckl (Edinburgh) & O Almeida (Munich, Germany)
|
| 08:15 |
S17
|
The role of androgens in the ageing male
A Matsumoto ( (Seattle, USA))
|
| 08:45 |
S18
|
Estrogen receptors in development and ageing
J Gustafsson ( (Novum, Sweden))
|
| 09:15 |
S19
|
Functional decline in mobility muscles and somatpause
F Martin (London)
|
| 09:45 |
S20
|
Stress hormones, innate immunity and ageing
J Lord ( (Birmingham))
|
| |
|
|
|
08.15 10.15
|
|
Oral Communications 3: Young Endocrinologists' prize session
Hall 9
Chairs: J Wass (Oxford) & J Buckingham (London)
|
| 08:15 |
OC16
|
Heterozygous missense mutations in steroidogenic factor 1 (SF1/Ad4BP, NR5A1) cause 46,XY disorders of sex development with normal adrenal function
L Lin;
P Philibert;
B Ferraz-de-Souza;
D Kelberman;
T Homfray;
A Albanese;
V Molini;
N Sebire;
S Einaudi;
L Jameson;
C Sultan;
M Dattani;
J Achermann;
|
| 08:30 |
OC17
|
Kisspeptin-54 potently stimulates luteinising hormone release during the preovulatory phase of the menstrual cycle in healthy human females.
Novartis Award Winner
O Chaudhri;
W Dhillo;
E Thompson;
K Murphy;
V Salem;
M Patterson;
M Donaldson;
V Amber;
R Ramachandran;
G Nijher;
A Kokkinos;
M Ghatei;
S Bloom;
|
| 08:45 |
OC18
|
Sedlin mutations disrupt interactions with pituitary homeobox 1 (Pitx1) and steroidogenic factor 1 (SF1): potential cause of delayed puberty in boys with Spondyloepiphyseal dysplasia tarda (SEDT)
J Jeyabalan;
M Nesbit;
H Ingraham;
R Thakker;
|
| 09:00 |
OC19
|
Steroidogenic gene transcription in the human hippocampus and cerebellum: a comprehensive survey
Novartis Award Winner
S MacKenzie;
D Dewar;
W Stewart;
R Fraser;
J Connell;
E Davies;
|
| 09:15 |
OC20
|
Insulin fails to limit proteolysis in critically ill medical patients to rates observed after cardiothoracic surgery
M Whyte;
N Jackson;
F Shojaee-Moradie;
R Beale;
D Treacher;
C Blauth;
R Jones;
M Umpleby;
|
| 09:30 |
OC21
|
Muscle cell differentiation is regulated by glucocorticoids, a process which is potentiated through the induction of 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1)
M Sherlock;
G Lavery;
J Horsburgh;
A Slabbert;
A Toogood;
P Stewart;
|
| 09:45 |
OC22
|
Mice deleted for a Multiple Endocrine Neoplasia Type 1 (MEN1) allele develop pancreatic, pituitary and parathyroid tumours in association with hypercalcaemia
M Lemos;
B Harding;
M Bowl;
A Reed;
H Tateossian;
T Hough;
W Fraser;
M Cheeseman;
R Thakker;
|
| 10:00 |
OC23
|
The corticotropin-releasing factor type 2 receptor selective ligand Urocortin 3 suppresses angiogenesis in vitro and in vivo
A Kozac;
T Pechenick Jowers;
P Hadoke;
W Vale;
P Jamieson;
|
| |
|
|
|
08:15 10:15
|
|
Clinical Management Workshop 2: Practical management aspects of PCOS
All you need for managing PCOS in the clinic
Supported by Clinical Endocrinology
Hall 1
Chairs: A Dunaif (Chicago, USA) & L Cho (Hull)
|
| 08:15 |
S49
|
The use of insulin sensitisers in the adolescent
D Dunger ( (Cambridge))
|
| 08:45 |
S50
|
The role of weight reduction strategies in the management of PCOS
N Finer ( (Cambridge))
|
| 09:15 |
S51
|
Practical aspects of managing subfertility in polycystic ovary syndrome
A Balen ( (Leeds))
|
| 09:45 |
S52
|
Management of the cosmetic aspects of PCOS
J O'Driscoll ( (Manchester))
|
| |
|
|
|
10:15 10:45
|
|
Coffee
Hall 3
|
| |
|
|
|
10:45 11:30
|
|
Society for Endocrinology Transatlantic Medal Lecture
The transcriptional co-activator PGC-1 alpha controls mitochondrial biogenesis and other aspects of energy homeostasis. This pathway might provide a unique opportunity to control obesity, diabetes and a number of other diseases involving dysregulation of energy homeostasis
Hall 1
Chair: S Bloom (London)
|
|
S2
|
PGC-1 co-activators and the control of energy homeostasis
B Spiegelman ( (Boston, USA))
|
| |
|
|
|
11.30 13.30
|
|
Lunch and attended posters
Posters 1-196 attended 12.30-13.00
Hall 3
|
| |
|
|
|
13.30 15.30
|
|
Symposium 4: Endocrine stem cells
Hype or hope?
Hall 1
Chairs: K Docherty (Aberdeen) & K Piper-Hanley (Southampton)
|
| 13:30 |
S21
|
Precursors to pancreatic beta cells
D Tosh ( (Bath))
|
| 14:00 |
S22
|
Replacing beta cells: proof-of-principle and the stem cell option
N Hanley ( (Southampton))
|
| 14:30 |
S23
|
Nuclear transfer and stem cell-based replacement therapies: tailored treatment
A Murdoch ( (Newcastle upon Tyne))
|
| 15:00 |
S24
|
Conditional ablation and regeneration of pancreatic beta cells
Y Dor ( (Jerusalem, Israel))
|
| |
|
|
|
13.30 15.30
|
|
Oral Communications 4: Neuroendocrinology, reproduction and cardiovascular
Hall 11
Chairs: D Ray (Manchester) & A Harte (Coventry)
|
| 13:30 |
OC24
|
Acute alderstone reponses to ACTH predict both cortisol responses and blood pressue
R Reynolds;
B Walker;
D Phillips;
H Syddall;
E Davies;
R Fraser;
J Connell;
|
| 13:45 |
OC25
|
Manipulation of proprotein convertase 1 expression in AtT20 cells changes pro-opiomelanocortin processing and trafficking: implications for ACTH regulatory pathways
T Day;
A Warhurst;
R Oliver;
L Pritchard;
A White;
|
| 14:00 |
OC26
|
Molecular mechanism of action of annexin A1 in controlling hormone release from neuroendocrine cells
E Solito;
H Christian;
J Buckingham;
|
| 14:15 |
OC27
|
Manganese-enhanced MRI demonstrates that oxyntomodulin and GLP-1 affect neuronal activity in distinct regions of the brain
O Chaudhri;
J Parkinson;
A Herlihy;
V Salem;
Y Kuo;
J Bell;
P So;
W Dhillo;
S Stanley;
M Ghatei;
S Bloom;
|
| 14:30 |
OC28
|
The effect of glucocorticoid withdrawal after long-term treatment on POMC and its transcription factors
A Eltobgi;
A Munir;
N Smith;
L Abbott;
J Newell-Price;
|
| 14:45 |
OC29
|
Effects of insulin-like growth factor 1 (IGF-1) on early folliculogenesis in polycystic ovaries from ovulatory and anovulatory women
S Stubbs;
K Hardy;
S Franks;
|
| 15:00 |
OC30
|
Consequences of variation in the CYP11B2 and CYP11B1 genes on hypothalamic-pituitary-adrenal axis activity
E Freel;
A White;
M Ingram;
R Fraser;
E Davies;
J Connell;
|
| 15:15 |
OC31
|
Evidence for associations between fibroblast growth factor 1 gene and human hypertension
2005 Pfizer Award winner
M Tomaszewski;
|
| |
|
|
|
13.30 15.30
|
|
Young Endocrinologists' Session: A sucessful research career
Hall 9
Chairs: K Jonas (London) & K Mullan (Belfast)
|
| 13:30 |
S68
|
MD versus PhD
A Munir ( (Sheffield))
|
| 14:00 |
S69
|
Managing your PhD
A White ( (Manchester))
|
| 14:30 |
S70
|
Fraud and Plagiarism
S Hillier ( (Edinburgh))
|
| 15:00 |
S71
|
Making money out of research
R Ross ( (Sheffield))
|
| |
|
|
|
15:30 16:00
|
|
Tea
Hall 3
|
| |
|
|
|
16:00 16:45
|
|
Society for Endocrinology Asia and Oceania Medal Lecture
A nuclear receptor Ad4BP/SF-1 is essential for steroidgenic tissue development. Investigation of the steroidogenic tissue-specific expression of this factor has elucidated mechanisms underlying the tissue development
Hall 1
Chair: D Ray (Manchester)
|
|
S3
|
From Ad4BP/SF-1 to cell and tissue differentiation
K Morohashi ( (Tokyo, Japan))
|
| |
|
|
|
16:45 17:45
|
|
Clinical Review Lecture
Hall 11
Chair: N Finer (Cambridge)
|
|
S75
|
Pharmacological aspects of appetite control
D Cooke ( (London))
|
| |
|
|
|
16:45 17:45
|
|
Clinical Debate: This house believes that all patiants with sub-clinical thyrotoxicosis should be treated
Hall 1
Chair: J Ahlquist (Westcliff on Sea)
|
|
D1
|
For the motion
S Pearce ( (Newcastle upon Tyne))
|
|
D2
|
Against the motion
M Vanderpump (London)
|
| |
|
|
|
16:45 17:45
|
|
Education Technology Session: Science
Hall 9
Chair: M Westwood (Manchester)
|
|
S76
|
Role of micro RNAs in development and disease
T Dalmay ( (Norwich))
|
| |
|
|
|
17:45 19:00
|
|
Young Endocrinologists' Social Evening
Hall 1, level 5a
|
| |
|
|
|
19:30 21:30
|
|
Special Interest Group Session: Polycystic ovary syndrome
Generously supported by Shire Pharmaceuticals
Hall 11
Chairs: S Atkin (Hull) & H Randeva (Warwick)
|
| 19:30 |
|
Follicular function and PCOS
H Mason (London)
|
| 20:00 |
|
Cardiovascular disease and PCOS
AM Colao (Naple, Italy)
|
| 20:30 |
|
Dermatology and PCOS
U Blume-Peytavi (Berlin, Germany)
|
| 21:00 |
|
Discussion
|
| |
|
|
| Wednesday 7 March
|
|
08.15 10.15
|
|
Symposium 5: Novel endocrine consequences of stress
The identification of novel ligands for the CRF-R2 receptor has uncovered new roles for these receptors outside the CNS
Hall 1
Chairs: D Grammatopoulos (Coventry) & P Jamieson (Edinburgh)
|
| 08:15 |
S25
|
New roles for the CRF-R2
E Hillhouse (Edinburgh)
|
| 08:45 |
S26
|
Exercise alters endocrine and behavioural consequences of stress
J Reul ( (Bristol))
|
| 09:15 |
S27
|
Corticotropin releasing hormone system and inflammation
K Karalis ( (Boston, USA))
|
| 09:45 |
S28
|
Urocortins and peripheral energy metabolism
A Chen (Rehovot, Israel)
|
| |
|
|
|
08.15 10.15
|
|
Symposium 6: Vitamin D - new perspectives
Clinicopathological facets of vitamin D
Hall 1
Chairs: M Hewison (Los Angeles) & S Xu (Hull)
|
| 08:15 |
S29
|
The Vitamin D receptor as a dual-functional mediator of endocrine and detoxification pathways
P Thompson ( (Londonderry))
|
| 08:45 |
S30
|
The epithelial calcium channels: uniquely regulated gatekeepers
J Hoenderop ( (Nijmegan, The Netherlands))
|
| 09:15 |
S31
|
Vitamin D and Cancer Prevention
M Campbell ( (Birmingham))
|
| 09:45 |
S32
|
Vitamin D and autoimmune disease
C Mathieu ( (Leuven, Belgium))
|
| |
|
|
|
08.15 10.15
|
|
Nurses' Session 1: Thyroid cancer - more than a lump in the neck
Hall 9
Chairs: V Thornton-Jones (Oxford) & C Gibson (Manchester)
|
| 08:15 |
S60
|
Helping the patient through different types of thyroid cancer
R Dyer ( (Torquay))
|
| 08:45 |
S61
|
Controlling calcium following thyroidectomy
M Morris ( (Newcastle upon Tyne))
|
| 09:15 |
S62
|
Patient groups and the nurse's involvement
S Gorick ( (Norwich))
|
| 09:45 |
S63
|
The thyroid cancer patient journey and the role of the clinical nurse specialist
J Hewett ( (Torquay))
|
| |
|
|
|
10.15 10.45
|
|
Coffee
Hall 3
|
| |
|
|
|
10.45 11.30
|
|
Society for Endocrinology European Medal Lecture
GH and IGF-I have direct and indirect effects on the cardiovascular system. They act both on cardiomyocytes and on endothelial function. Consequently, alterations of the GH/IGF-1 axis induce cardiovascular diseases
Hall 1
Chair: J Wass (Oxford)
|
|
S4
|
GH/IGF-I and the cardiovascular system
A Colao (Naples, Italy)
|
| |
|
|
|
11:30 13:30
|
|
Lunch and attended posters
Posters 197-342 attended 12.00-12.30, all posters attended 12.30-13.00. Novartis award poster session 12.30
Hall 3
|
| |
|
|
|
13.30 15.30
|
|
Symposium 7: Animal disease, paradigm for human conditions
Aetiology, diagnosis and management of endocrine disease in domestic animals - any lesssons for human disease?
Hall 11
Chairs: J Bevan (Aberdeen) & D Church (Hatfield)
|
| 13:30 |
S33
|
Hyperadrenocorticism - current treatment options
D Church ( (Hatfield))
|
| 14:00 |
S34
|
Stress and sex on the farm - lessons for humans
H Dobson ( (Liverpool))
|
| 14:30 |
S35
|
Canine Diabetes Mellitus
B Catchpole ( (Hatfield))
|
| 15:00 |
S36
|
Feline hyperthyroidism: parallels with human hyperthyroidism
L Blackwood ( (Liverpool))
|
| |
|
|
|
13.30 15.30
|
|
Oral Communications 5: Thyroid and metabolism
Supported by the Clinical Endocrinology Trust
Hall 1
Chairs: J Newell-Price (Sheffield) & G Williams (London)
|
| 13:30 |
OC32
|
Extreme Insulin Resistance Syndromes - Beyond Glucose Homeostasis
Society for Endocrinology/Clinical Endocrinology Trust Young Endocrinologist Clinical Prize Lecture
R Semple;
|
| 14:00 |
OC33
|
Tag SNP screening of the PDCD1 gene for association with Graves’ disease
P Newby;
E Roberts-Davies;
O Brand;
J Heward;
J Franklyn;
S Gough;
M Simmonds;
|
| 14:15 |
OC34
|
Monocarboxylate transporter 8 (MCT8) represses proliferation of fetal embryonal NT2 and placental JEG-3 cells in vitro
British Thyroid Association award winner
S James;
C McCabe;
B Reaves;
V Smith;
S Chan;
T Barrett;
M Kilby;
J Franklyn;
|
| 14:30 |
OC35
|
A prothrombotic clot structure in hyperthyroidism: A mechanism for increased thrombosis in hyperthyroid individuals?
R Ajjan;
S Orme;
K Standeven;
F Phoenix;
V Hundia;
P Grant;
|
| 14:45 |
OC36
|
Comparsion of the NFκB and JNK mediated inflammatory mechanisms for production of adipocytokines in paired human epicardial and gluteo-femoral adipose tissue from CABG patients.
A Baker;
A Harte;
N da Silva;
M Hill;
A Ranasinghe;
K Khunti;
M Davies;
D Pagano;
R Bonser;
S Kumar;
P McTernan;
|
| 15:00 |
OC37
|
Testosterone replacement therapy attenuates fatty streak formation and improves the high-density lipoprotein cholesterol profile in the Testicular feminised (Tfm) mouse: an effect which is independent of the classical androgen receptor
J Nettleship;
R Jones;
K Channer;
H Jones;
|
| 15:15 |
OC38
|
The novel thyroid hormone derivative 3-iodothyronamine increases food intake via the hypothalamic arcuate nucleus
N White;
W Dhillo;
G Bewick;
J Gardiner;
J Scutt;
E Thompson;
A Kokkinos;
A Armstrong;
M Ghatei;
S Bloom;
|
| |
|
|
|
13:30 15:30
|
|
Nurses' Session 2: Dealing with MEN
Hall 9
Chairs: A Catteau (Sounthampton) & K Campbell (Glasgow)
|
|
|
Resumé
S Ball (Newcastle upon Tyne)
|
| 13:30 |
S64
|
Dealing with MEN: an overview
S Ball ( (Newcastle upon Tyne))
|
| 14:00 |
S65
|
Genetic counsellor contribution to the MEN patient
N Bradshaw ( (Glasgow))
|
| 14:30 |
S66
|
A paediatric perspective
L Martin ( (London))
|
| 15:00 |
S67
|
Adult Case
S Owusu-Antwi (London)
|
| |
|
|
|
15:30 16:00
|
|
Tea
Hall 3
|
| |
|
|
|
15:30 16:00
|
|
Nurses' Tea
Generously supported by Ipsen Ltd, poster boards by Novartis Oncology
Hall 1 level 5a
|
| |
|
|
|
16:00 17:00
|
|
The British Thyroid Association Pitt-Rivers Lecture - Incorporating Society for Endocrinology award ceremony
Thyroid hormone is well known to be important for growth and development. Recent studies of thyroid hormone receptors and deiodinases have revealed new developmental functions for this hormone, including sensory systems
Hall 1
Chair: A Weetman (Sheffield)
|
| 16:00 |
S5
|
Genes that mediate thyroid hormone functions in development
D Forrest ( (Bethesda, USA))
|
| |
|
|
|
17.00 17.45
|
|
Clinical Endocrinology Trust Visiting Professor Lecture
We have recently mapped an important polycystic ovary syndrome (PCOS) susceptibility allele. We propose that hyperandrogenemia resulting from variation in gene(s) regulation steroidogenesis contributes to PCOS reproductive and metabolic phenotypes by programming actions at critical periods of development as well as by ongoing actions in the adult.
Hall 1
Chair: L Rees (London)
|
|
S6
|
Genes and environment in the pathogenesis of polycystic ovary syndrome
A Dunaif ( (Chicago, USA))
|
| |
|
|
|
19.30
|
|
Society for Endocrinology Banquet
Burlington Hotel
|
| |
|
|
| Thursday 8 March
|
|
07:15 08:00
|
|
Clinical Expert 3: How should we screen for Cushing's syndrome?
Hall 9
Chair: J Newell-Price (Sheffield)
B Atkinson (Belfast)
|
| |
|
|
|
07:15 08:00
|
|
Clinical Expert 4: Erectile dysfunction and androgens
Genourously supported by Ipsen Ltd
Hall 11
Chair: N Hanley (Southampton)
P Bouloux (London)
|
| |
|
|
|
08:15 08:50
|
|
Society for Endocrinology Medal Lecture
What happens to cortisol in obesity and metabolic syndrome, what effect does cortisol have on the outcomes of cardiovascular disease, and is inhibition of 11beta-HSD1 the answer?
Hall 1
Chair: J Buckingham (London)
|
|
S7
|
Cortisol and cardiovascular disease: from cradle to grave
B Walker ( (Edinburgh))
|
| |
|
|
|
08:55 09:30
|
|
Clinical Endocrinology Trust Lecture
There is increasing awareness that defective intracellular trafficking of molecules leads to disease. This is illustrated by recent findings in ACTH insensitivity syndromes causing adrenal insufficiency
Hall 1
Chair: L Rees (London)
|
|
S8
|
Failing to stop, failing to signal, no insurance, and other trafficking defects in the adrenal
A Clark ( (London))
|
| |
|
|
|
09:30 10:00
|
|
Coffee
Hall 3
|
| |
|
|
|
10:00 12:00
|
|
Clinical Management Workshop 3: New aspects of phaeochromocytoma
New genetic syndromes have changed the management of patients with sporadic phaeocromocytoma
Supported by Clinical Endocrinology
Hall 1
Chairs: J Connell (Glasgow) & M Brown (Cambridge)
|
| 10:00 |
S53
|
Familial phaeochromocytoma syndromes
E Maher ( (Birmingham))
|
| 10:30 |
S54
|
New Aspects of phaeochromocytoma: managing young people with phaeochromocytoma
S Ball ( (Newcastle upon Tyne))
|
| 11:00 |
S55
|
Biochemical testing - which test in which patient
R Peaston ( (Newcastle upon Tyne))
|
| 11:30 |
S56
|
Clinical case discussion
S Ritchie (Glasgow)
|
| |
|
|
|
10:00 11:30
|
|
Clinical Management Workshop 4: Differentiated thyroid cancer
An overview of the ideal sugical approach to thyroid cancer
Supported by Clinical Endocrinology
Hall 11
Chairs: J Lazarus (Cardiff) & M Strachan (Edinburgh)
|
| 10:00 |
S57
|
Clinical management of thyroid cancer: new guidelines
P Perros ( (Newcastle upon Tyne))
|
| 10:30 |
S58
|
Surgical management of differentiated thyroid cancer
B Harrison ( (Sheffiled))
|
| 11:00 |
S59
|
An update in the management practices of thyroid cancer and the use of rhTSH
M Schlumberger ( (Villejuif, France))
|
| |
|
|
|
12:00 12:45
|
|
Clinical Expert 5: Endocrine hypertension
Hall 9
Chair: P Stewart (Birmingham)
M Brown (Cambridge)
|
| |
|
|
|
12:00 12:45
|
|
Clinical Expert 6: New developments in risk reduction in diabetes
Hall 11
Chair: M Gibson (Manchester)
TBC
|
| |
|
|
|
12:45 13:15
|
|
Lunch and posters
Hall 3
|
| |
|
|
|
13:15 15:15
|
|
Symposium 8: Aspects of cardiovascular risk management in diabetes
New approaches to the management of cardiovascular risk in diabetes are urgently required. This symposium will address new therapeutic targets in metabolic syndrome and in type 1 and type 2 diabetes.
Genourously supported by AstraZeneca Plc
Hall 1
Chairs: P Durrington (Manchester) & J Petrie (Dundee)
|
| 13:15 |
S37
|
The value of PPAR agonists in relation to endothelial function
J Petrie (Dundee)
|
| 13:45 |
S38
|
Developments in the dyslipidaemia of diabetes
C Packard ( (Glasgow))
|
| 14:15 |
S39
|
Cardiovascular risk and risk management in type 1 diabetes
N Chaturvedi ( (London))
|
| 14:45 |
S40
|
Aldosterone Induced Vascular Inflammatory Disease: Mechanisms and Implications for Clinical Practice
R Rocha ( (Novartis Pharmaceuticals))
|
| |
|
|
|
13:15 14:45
|
|
Symposium 9: New biology of bone: therapeutic implications
Recently, serveral new insights have been gained into the signalling between bone cells. These discoveries have now been translated into novel treatments for bone diseases, especially osteophorosis. This symposium explores this new understanding of bone physiology and how the lessons learned can be translated into clinical practice.
Genorously supported by Amgen
Hall 11
Chairs: M Cooper (Birmingham) & P Selby (Manchester)
|
| 13:15 |
S41
|
LRP5
A Koay (GE Healthcare)
|
| 13:45 |
S42
|
Osteoclast differentiation and function
T Chambers ( (London))
|
| 14:15 |
S43
|
Rank Modulation in Treatment
M McClung ( (Portland, USA))
|
| 14:45 |
S44
|
Emerging new targets for home therapy. Cathespsins, WNTs, calcilytics and other approaches
G Russell (Oxford)
|
| |
|
|